Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Capital Expenditures (2019 - 2025)

Korro Bio (KRRO) has disclosed Capital Expenditures for 6 consecutive years, with $175000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures fell 96.41% year-over-year to $175000.0, compared with a TTM value of $1.9 million through Sep 2025, down 89.58%, and an annual FY2024 reading of $17.9 million, up 128.46% over the prior year.
  • Capital Expenditures was $175000.0 for Q3 2025 at Korro Bio, up from $140000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.0 million in Q2 2024 and bottomed at -$1.0 million in Q2 2021.
  • Average Capital Expenditures over 5 years is $1.8 million, with a median of $1.5 million recorded in 2024.
  • The sharpest move saw Capital Expenditures plummeted 213.53% in 2021, then soared 110450.0% in 2023.
  • Year by year, Capital Expenditures stood at $61000.0 in 2021, then surged by 8319.67% to $5.1 million in 2022, then tumbled by 67.78% to $1.7 million in 2023, then decreased by 12.27% to $1.5 million in 2024, then crashed by 87.95% to $175000.0 in 2025.
  • Business Quant data shows Capital Expenditures for KRRO at $175000.0 in Q3 2025, $140000.0 in Q2 2025, and $119000.0 in Q1 2025.